{
    "clinical_study": {
        "@rank": "131174", 
        "acronym": "ARTSCANIII", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 1-4)."
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 3-4)."
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 1-4)."
            }, 
            {
                "arm_group_label": "Arm 4", 
                "arm_group_type": "Experimental", 
                "description": "Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 3-4)."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary endpoint in this study is to investigate if there is a difference in overall\n      survival in patients with locally advanced head and neck cancer, randomized to either\n      radiotherapy and cetuximab or radiotherapy and cisplatin. A second randomization is\n      performed in patients with T3-T4 tumors; allocated radiotherapy either 68.0 Gy or 73.1 Gy."
        }, 
        "brief_title": "A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.", 
        "condition": "Locally Advanced Head and Neck Cancer.", 
        "condition_browse": {
            "mesh_term": "Head and Neck Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age at least 18 years\n\n          -  Histologically or cytologically confirmed , previous untreated head and neck squamous\n             cell cancer of the oral cavity, hypopharynx, larynx or of the oral cavity aimed for\n             unimodal treatment with radiotherapy with curative intent\n\n          -  Tumor stage III and IV , but no evidence of distant metastases beyond the regional\n             nodes in the neck\n\n          -  WHO/Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\n          -  The patient must be expected to withstand radiotherapy combined with cisplatin or\n             cetuximab\n\n          -  The patient must be able to understand the information about the treatment and give a\n             written informed concent to participate in the trial\n\n          -  Adequate follow-up study must be possible; this will exclude a patient who is\n             uncooperative\n\n          -  Adequate renal function, creatinine clearance over 50 ml/min/1.73 estimated according\n             to local practice at each study centre\n\n        Exclusion Criteria:\n\n          -  Previous malignant disease in the head and neck region, with exception for basal cell\n             carcinoma or curatively treated squamous cell carcinoma of the skin with follow-up\n             time of at least 3 years\n\n          -  Concomitant or previous malignancies. Exceptions are adequately treated basal cell\n             carcinoma or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix\n             uteri, or other previous malignancy with a disease-free interval of at least 5 years\n\n          -  Two or more synchronous primary head and neck squamous cell cancer at time of\n             diagnosis\n\n          -  Co-existing disease prejudicing survival (expected survival less than 6 months)\n\n          -  Absolute neutrophil count less than 1.5 x 109/L\n\n          -  Platelet count less than 100 x 109/L\n\n          -  Bilirubin over 1.5 times upper limit of normal\n\n          -  Aspartate aminotransferase (ASAT) or Alanine aminotransferase (ALAT) more than 3\n             times upper limit of normal\n\n          -  Pregnancy or lactation\n\n          -  Allergy to study drug or to the excipients in their formulation\n\n          -  Neuropathy grade 2 or more according to Common terminology criteria for adverse\n             events (CTCAE) v.4.0\n\n          -  Hearing loss/tinnitus is a relative exclusion criteria; the responsible physician\n             decides whether the patient may be included in the study\n\n          -  Severe cardiac illness; myocardial infarction within 6 months prior to randomization,\n             severe congestive heart failure, severe cardiomyopathy, ventricular arrythmia,\n             unstable angina, uncontrolled hypertension"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "618", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969877", 
            "org_study_id": "EudraCT number 2012-001879-37", 
            "secondary_id": "2012-001879-37"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2", 
                    "Arm 3", 
                    "Arm 4"
                ], 
                "intervention_name": "cetuximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2", 
                    "Arm 3", 
                    "Arm 4"
                ], 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cetuximab", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Head and neck cancer", 
            "Cetuximab", 
            "Cisplatin", 
            "Radiotherapy", 
            "Quality of life", 
            "Human papilloma virus", 
            "Health economy", 
            "Biomarker investigations"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Stefan Bergstr\u00f6m, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "G\u00e4vle", 
                        "country": "Sweden"
                    }, 
                    "name": "G\u00e4vle Hospital"
                }, 
                "investigator": {
                    "last_name": "Stefan Bergstr\u00f6m, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hedda Haugen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "G\u00f6teborg", 
                        "country": "Sweden"
                    }, 
                    "name": "Sahlgrenska University Hospital"
                }, 
                "investigator": {
                    "last_name": "Hedda Haugen, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mats Olin, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "J\u00f6nk\u00f6ping", 
                        "country": "Sweden"
                    }, 
                    "name": "County Hospital Ryhov"
                }, 
                "investigator": {
                    "last_name": "Mats Olin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Britta L\u00f6d\u00e9n, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Karlstad", 
                        "country": "Sweden"
                    }, 
                    "name": "Central Hospital"
                }, 
                "investigator": {
                    "last_name": "Britta L\u00f6d\u00e9n, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Maciej Tytor, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Link\u00f6ping", 
                        "country": "Sweden"
                    }, 
                    "name": "University Hospital Link\u00f6ping"
                }, 
                "investigator": {
                    "last_name": "Maciej Tytor, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Signe Friesland, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden"
                    }, 
                    "name": "Karolinska Universityhospital"
                }, 
                "investigator": {
                    "last_name": "Signe Friesland, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Karin S\u00f6derstr\u00f6m, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Ume\u00e5", 
                        "country": "Sweden"
                    }, 
                    "name": "Norrland University Hospital"
                }, 
                "investigator": {
                    "last_name": "Karin S\u00f6derstr\u00f6m, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Zuzana Lovasova, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "V\u00e4ster\u00e5s", 
                        "country": "Sweden"
                    }, 
                    "name": "V\u00e4stmanlands Hospital V\u00e4ster\u00e5s"
                }, 
                "investigator": {
                    "last_name": "Zuzana Lovasova, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Johan Reizenstein, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "\u00d6rebro", 
                        "country": "Sweden"
                    }, 
                    "name": "University Hospital \u00d6rebro"
                }, 
                "investigator": {
                    "last_name": "Johan Reizenstein, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized Multicenter Phase III Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.", 
        "overall_contact": {
            "email": "maria.gebre-medhin@skane.se", 
            "last_name": "Maria Gebre-Medhin, MD, PhD", 
            "phone": "+46 46 17 75 20"
        }, 
        "overall_contact_backup": {
            "email": "irene.schonstrom@skane.se", 
            "last_name": "Ir\u00e9ne Sch\u00f6nstr\u00f6m, RN", 
            "phone": "+46 46 17 85 59"
        }, 
        "overall_official": {
            "affiliation": "Lund University Hospital", 
            "last_name": "Maria Gebre-Medhin, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2024", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "Every 3 month for 2 years, and every 6 month until 5 years for evaluation of overall survival"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969877"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Lund University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lund University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}